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1. INTRODUCTION {#jcla23023-sec-0005}
===============

Asthma, a highly prevalent chronic respiratory disease, affects approximately three hundred million people globally.[1](#jcla23023-bib-0001){ref-type="ref"} Clinically, asthma is characterized by reversible airway obstruction, airway hyper‐responsiveness, and airway inflammation‐related symptoms, such as breathlessness, chest tightness, and dyspnea.[2](#jcla23023-bib-0002){ref-type="ref"} Asthma exacerbations are acute episodes of asthma symptoms, defined as decreases in expiratory airflows and objective measures of lung function. Once severe exacerbation occurs, patients experience decline of lung function as well as severe airflow obstruction, which contributes to more frequent severe exacerbation in the future.[3](#jcla23023-bib-0003){ref-type="ref"}, [4](#jcla23023-bib-0004){ref-type="ref"} Current effective pharmacologic interventions for reducing the asthma symptoms consist of inhaled corticosteroids, long‐acting beta‐agonists, leukotriene modifiers, and anti‐IgE therapy; however, still a large number of asthmatics experience exacerbations despite guideline‐directed treatment.[5](#jcla23023-bib-0005){ref-type="ref"}, [6](#jcla23023-bib-0006){ref-type="ref"}, [7](#jcla23023-bib-0007){ref-type="ref"} Therefore, discovery of potential biomarkers is necessary to identify the risk of asthma exacerbation, which would improve disease control and optimizes the treatment outcomes.

Recently, increasing evidence demonstrates the implication of long non‐coding RNA (lncRNA) in the onset and development of respiratory diseases and inflammation‐related diseases.[8](#jcla23023-bib-0008){ref-type="ref"}, [9](#jcla23023-bib-0009){ref-type="ref"} *LncRNA nuclear‐enriched abundant transcript 1* (*NEAT1*) is encoded by the *NEAT1 gene* and promotes the activation of several inflammasomes in diverse diseases, including sepsis, colitis, and lupus.[10](#jcla23023-bib-0010){ref-type="ref"}, [11](#jcla23023-bib-0011){ref-type="ref"}, [12](#jcla23023-bib-0012){ref-type="ref"} Furthermore, one study elucidates that *lncRNA NEAT1* promotes myocardial ischemia‐reperfusion injury via increasing reactive oxygen species (ROS) level, and ROS is an effective predictor for severe exacerbations of asthma; thus, *lncRNA NEAT1* is speculated to be involved in the pathology of asthma exacerbation as well.[13](#jcla23023-bib-0013){ref-type="ref"} Additionally, microRNAs (miRNAs) are a group of small non‐coding RNAs, and existing studies confirm the interactions between *lncRNA NEAT1* and *miR‐124* through a competing endogenous RNA (ceRNA) regulatory network.[14](#jcla23023-bib-0014){ref-type="ref"} And mechanically, *miR‐124* contributes to development and maintenance of anti‐inflammatory phenotype in lung macrophages of asthma.[15](#jcla23023-bib-0015){ref-type="ref"} Considering the previous evidence, we hypothesized that *lncRNA NEAT1* might play an important role in the development and exacerbation of asthma, while there is still no related research reported currently. Thus, we conducted this study to explore the association of circulating *lncRNA NEAT1* expression with exacerbation risk, lung function, and inflammatory cytokines in asthma.

2. MATERIALS AND METHODS {#jcla23023-sec-0006}
========================

2.1. Participants {#jcla23023-sec-0007}
-----------------

From January 2017 to December 2018, 170 patients with asthma in exacerbation, 170 patients with asthma in remission, and 170 healthy controls (HCs) were enrolled at our hospital in this case‐control study. The inclusion criteria for patients with asthma in exacerbation were as follows: (a) confirmed diagnosis of asthma in accordance with the Global Initiative for Asthma (GINA) guideline (2016)[16](#jcla23023-bib-0016){ref-type="ref"}; (b) presenting with an acute worsening in symptoms including breathlessness, chest tightness, dyspnea, and increased cough; and (c) age more than 18 years. And the following patients were excluded: (a) cardiac asthma, bronchogenic carcinoma, endometrial lesions of trachea, or allergic pulmonary infiltration; (b) suffering from autoimmune disorders, hematological diseases, or serious infections; (c) complicated with malignancies or solid tumors; and (d) pregnant or lactating women. The inclusion criteria for patients with asthma in remission were as follows: (a) confirmed diagnosis of asthma in accordance with the Global Initiative for Asthma (GINA) guideline (2016)[16](#jcla23023-bib-0016){ref-type="ref"}; (b) presenting with clinical remission status, which was defined as after treatment or without treatment, the symptoms and signs disappeared, and the pulmonary function recovered to the pre‐acute level and maintained for at least 3 months; and (c) age more than 18 years. And the exclusion criteria for patients with asthma in remission were as same as the patients with asthma in exacerbation, including (a) cardiac asthma, bronchogenic carcinoma, endometrial lesions of trachea, or allergic pulmonary infiltration, (b) suffering from autoimmune disorders, hematological diseases, or serious infections, (c) complicated with malignancies or solid tumors, and (d) pregnant or lactating women. In addition, HCs were recruited from Health Examination Center of our hospital, when they were undergoing health examination at the same period. All of them were presenting with normal lung function and had no history of asthma, allergic diseases, autoimmune disorders, hematological diseases, serious infections, or malignancies.

2.2. Ethics statement {#jcla23023-sec-0008}
---------------------

The Institutional Review Board of our hospital approved this study, and all participants provided written informed consents before enrollment.

2.3. Data collection {#jcla23023-sec-0009}
--------------------

After collection of written informed consents, basic characteristics of all participants were recorded including age, gender, family history of asthma, and the biochemical index (immune globulin E (IgE)). And the measurement of pulmonary ventilation function was also performed for all participants, which included forced expiratory volume in 1 second (FEV~1~) and forced vital capacity (FVC), and then, the values of FEV~1~/FVC and FEV~1~%predicted were calculated. Besides, the disease severity of the patients with asthma in exacerbation was evaluated according to The Global Strategy for Asthma Management and Prevention (updated 2010) (www. ginasthma.org) (details shown in the Table [S1](#jcla23023-sup-0001){ref-type="supplementary-material"}) and documented on the hospital admission.

2.4. Sample collection {#jcla23023-sec-0010}
----------------------

On the enrollment, blood samples were collected from all eligible participants using vacuum blood collection tubes containing ethylene diamine tetraacetic acid (EDTA). The collected samples were immediately centrifuged at 1600 *g* for 15 minutes (4°C) to obtain supernatant; then, the supernatant was centrifuged one more time at 16 000 *g* for 10 minutes (4°C) to isolate plasma. Finally, the isolated plasma was stored at −80°C until analysis.

2.5. Real‐time quantitative polymerase chain reaction (RT‐qPCR) {#jcla23023-sec-0011}
---------------------------------------------------------------

The expression of *lncRNA NEAT1* and *miR‐124* (which was *miR‐124‐5p* in detail with accession number MIMAT0004591) in the plasma of participants was detected by the RT‐qPCR. The total RNA was extracted from plasma using TRIzol™ Reagent (Thermo Fisher Scientific) and then reversely transcribed to cDNA using PrimeScript™ RT reagent Kit (Perfect Real Time) (Takara). Following that, RT‐qPCR was performed using SYBR^®^ Premix DimerEraser™ (Takara) to quantify *lncRNA NEAT1* (GAPDH as internal reference) and *miR‐124* expressions (U6 as internal reference). The procedures were carried out as follows: first, 5 minutes at 95 degrees centigrade, 40 cycles of PCR then followed by standard conditions with 15 seconds denaturation at 95 degrees centigrade, and next elongation for 1 minute at 60 degrees centigrade. And the result was calculated using 2^−△△Ct^ method. Primers were as follows: *lncRNA NEAT1*, forward (5ʹ‐\>3ʹ): TGTCCCTCGGCTATGTCAGA, reverse (5ʹ‐\>3ʹ): GAGGGGACGTGTTTCCTGAG; *miR‐124*, forward (5ʹ‐\>3ʹ): ACACTCCAGCTGGGCGTGTTCACAGCGGACCT, reverse (5ʹ‐\>3ʹ): TGTCGTGGAGTCGGCAATTC; *GAPDH*, forward (5ʹ‐\>3ʹ): GAGTCCACTGGCGTCTTCAC, reverse (5ʹ‐\>3ʹ): ATCTTGAGGCTGTTGTCATACTTCT; U6, forward (5ʹ‐\>3ʹ): CTCGCTTCGGCAGCACATATACTA, reverse (5ʹ‐\>3ʹ): ACGAATTTGCGTGTCATCCTTGC.

2.6. Enzyme‐linked immunosorbent assay {#jcla23023-sec-0012}
--------------------------------------

The inflammatory cytokines including tumor necrosis factor alpha (TNF‐α), interleukin‐1 beta (IL‐1β), interleukin‐10 (IL‐10), and interleukin‐17 (IL‐17) in the plasma were determined by Enzyme‐linked immunosorbent assay (ELISA) with ELISA kits, including Human TNF‐α ELISA Kit (Thomas, KHC3014), Human IL‐1β ELISA Kit (Thomas, BMS224HS), Human IL‐10 ELISA Kit (Abcam, ab100549), and Human IL‐17 ELISA Kit (Abcam, ab83707), which were ready‐to‐use, according to the instructions of manufacturer. In brief, firstly, samples or standards were added to the 96‐well plates, followed by the antibody mix. After incubation, the wells were washed to remove unbound material. TMB substrate (tetramethylbenzidine, TMB) was added, generating blue coloration. This reaction was then stopped by addition of Stop Solution completing any color change from blue to yellow. Signal was generated proportionally to the amount of bound analyte (Biotek), and the intensity was measured at 450 nm. Each reaction was run in triplicate by the same operator. Standard curves were prepared before the antibody reaction, and the standard curve range of Human TNF‐α ELISA Kit (Thermo, KHC3014), Human IL‐1β ELISA Kit (Thermo, BMS224HS), Human IL‐10 ELISA Kit (Abcam, ab100549), and Human IL‐17 ELISA Kit (Abcam, ab83707) were 0.5‐32pg/mL, 0.16 ‐10 pg/mL, 2.34‐150 pg/mL, and 3.12‐100 pg/mL, respectively.

2.7. Statistical analysis {#jcla23023-sec-0013}
-------------------------

Statistical data processing was carried out using SPSS 20.0 software (IBM Corp.), and all figures were made by GraphPad Prism 7.01 software (GraphPad Software Inc). Data were described as the mean and standard deviation (SD), median and interquartile range (IQR), or number (percentage) according to the distribution of data. Difference among three groups was determined by one‐way analysis of variance (ANOVA) and Kruskal‐Wallis test followed by the Dunn\'s multiple comparison test or chi‐square test. Correlation between variables was assessed by the Spearman\'s rank correlation test. The receiver operating characteristic (ROC) curve, the area under the curve (AUC), and 95% confidence interval (CI) were used to assess the performance of variables in distinguishing different subjects. All tests were presented as two‐sided, and *P* value \< .05 was considered statistically significant.

3. RESULTS {#jcla23023-sec-0014}
==========

3.1. Baseline characteristics {#jcla23023-sec-0015}
-----------------------------

The mean age was 37.6 ± 7.9 years of patients with asthma in exacerbation, 36.3 ± 8.0 years of patients with asthma in remission, and 36.4 ± 6.9 years of HCs (Table [1](#jcla23023-tbl-0001){ref-type="table"}). There were 88 (51.8%) males and 82 (48.2%) females in patients with asthma in exacerbation, 99 (58.2%) males and 71 (41.8%) females in patients with asthma in remission, and 98 (57.6%) males and 72 (42.4%) females in the HCs. No difference of age or gender was observed among patients with asthma in exacerbation, patients with asthma in remission, and HCs (both *P* \> .05). However, family history of asthma, IgE, lung function, and inflammatory cytokines were different among the three groups. The detailed information of participants\' characteristics was listed in Table [1](#jcla23023-tbl-0001){ref-type="table"}.

###### 

Characteristics of participants

+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Items                                                     | Asthma in exacerbation | Asthma in remission | HCs                | *P* value |
|                                                           |                        |                     |                    |           |
|                                                           | (N = 170)              | (N = 170)           | (N = 170)          |           |
+===========================================================+========================+=====================+====================+===========+
| Age (y), mean ± SD                                        | 37.6 ± 7.9             | 36.3 ± 8.0          | 36.4 ± 6.9         | .220      |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Gender, No. (%)                                           |                        |                     |                    |           |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Male                                                      | 88 (51.8)              | 99 (58.2)           | 98 (57.6)          | .414      |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Female                                                    | 82 (48.2)              | 71 (41.8)           | 72 (42.4)          |           |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Family history of asthma, No. (%)                         |                        |                     |                    |           |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| No                                                        | 120 (70.6)             | 135 (79.4)          | 146 (85.9)         | .003      |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Yes                                                       | 50 (29.4)              | 35 (20.6)           | 24 (14.1)          |           |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Biochemical indexes, median (IQR)                         |                        |                     |                    |           |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| IgE (IU/mL)                                               | 225.9 (147.1‐342.9)    | 76.5 (52.9‐120.5)   | 30.9 (16.4‐47.0)   | \<.001    |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Lung function indexes, median (IQR)                       |                        |                     |                    |           |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| FEV~1~/FVC (%)                                            | 66.6 ± 6.6             | 80.1 ± 4.6          | 83.2 ± 4.7         | \<.001    |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| FEV~1~%predicted (%)                                      | 76.0 ± 5.8             | 84.6 ± 5.0          | 100.2 ± 6.9        | \<.001    |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Inflammatory cytokines, median (IQR)                      |                        |                     |                    |           |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| TNF‐α (pg/mL)                                             | 50.9 (33.7‐78.4)       | 20.46 (10.10‐30.84) | 12.97 (7.29‐18.87) | \<.001    |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| IL‐1β (pg/mL)                                             | 3.6 (2.1‐4.8)          | 1.3 (0.6‐2.1)       | 0.8 (0.5‐1.2)      | \<.001    |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| IL‐10 (pg/mL)                                             | 7.6 (6.7‐10.6)         | 15.1 (10.6‐24.4)    | 18.9 (13.3‐29.1)   | \<.001    |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| IL‐17 (pg/mL)                                             | 42.4 (22.5‐88.3)       | 16.0 (5.9‐33.8)     | 10.4 (5.2‐16.1)    | \<.001    |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Exacerbation severity, No. (%)                            |                        |                     |                    |           |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Mild                                                      | 42 (24.7)              | --                  | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Moderate                                                  | 89 (52.4)              | --                  | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Severe                                                    | 39 (22.9)              | --                  | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| Medicine use within 3 mo, No. (%)                         |                        |                     |                    | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| ICS                                                       | --                     | 103 (60.6)          | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| ICS + LTRA                                                | --                     | 38 (22.4)           | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| ICS + β2‐agonists                                         | 60 (35.3)              | --                  | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| ICS + β2‐agonists + theophylline                          | 36 (21.2)              | --                  | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| ICS + β2‐agonists + anticholinergics                      | 48 (28.2)              | --                  | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+
| ICS + β2‐agonists + anticholinergics +anti‐IgE antibody） | 26 (15.3)              | --                  | --                 | --        |
+-----------------------------------------------------------+------------------------+---------------------+--------------------+-----------+

Comparisons were determined by one‐way ANOVA, chi‐square test, or Kruskal‐Wallis H rank sum test.

Abbreviations: FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; HCs, healthy controls; ICS, inhaled corticosteroids; IgE, immune globulin E; IL, interleukin; IQR, interquartile range; LTRA, leukotriene receptor antagonists; SD, standard deviation; TNF, tumor necrosis factor.
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3.2. Correlation of *lncRNA NEAT1* with exacerbation risk of asthma {#jcla23023-sec-0016}
-------------------------------------------------------------------

The *lncRNA NEAT1* relative expression was increased in patients with asthma in exacerbation compared with patients with asthma in remission (*P* \< .001) and HCs (*P* \< .001) (Figure [1](#jcla23023-fig-0001){ref-type="fig"}A). And the *lncRNA NEAT1* relative expression was increased in patients with asthma in remission compared with HCs (*P* \< .001). ROC curve presented that *lncRNA NEAT1* relative expression was of good value in distinguishing patients with asthma in exacerbation from HCs (AUC: 0.869 (0.830‐0.908)) (Figure [1](#jcla23023-fig-0001){ref-type="fig"}B) and patients with asthma in remission (AUC: 0.775 (0.724‐0.825)) (Figure [1](#jcla23023-fig-0001){ref-type="fig"}C). It could also distinguish patients with asthma in remission from HCs (AUC: 0.631 (0.572‐0.690)) (Figure [1](#jcla23023-fig-0001){ref-type="fig"}D). These data indicated that *lncRNA NEAT1* could predict exacerbation risk of asthma.

![*LncRNA NEAT1* relative expression in asthma. The comparison of *lncRNA NEAT1* relative expression among HCs, patients with asthma in remission, and patients with asthma in exacerbation (A). The performance of *lncRNA NEAT1* in distinguishing asthma in exacerbation from HCs (B), asthma in exacerbation from asthma in remission (C), and asthma in remission from HCs (D). Comparisons among three groups were conducted by Kruskal‐Wallis test followed by the Dunn\'s multiple comparisons test. And ROC curves were used to assess the ability of *lncRNA NEAT1* in distinguishing HCs, patients with asthma in remission, and patients with asthma in exacerbation. *P* \< .05 was considered significant. *LncRNA NEAT1*, *long non‐coding RNA nuclear‐enriched abundant transcript 1*; HCs, healthy controls; ROC, receiver operating characteristic](JCLA-34-e23023-g001){#jcla23023-fig-0001}

3.3. Correlation of *lncRNA NEAT1* with exacerbation severity in asthma patients with exacerbation {#jcla23023-sec-0017}
--------------------------------------------------------------------------------------------------

The *lncRNA NEAT1* relative expression was different among patients with asthma in mild (n = 42), moderate (n = 89), and severe (n = 39) exacerbation severity (*P* \< .001) (Figure [2](#jcla23023-fig-0002){ref-type="fig"}). The *lncRNA NEAT1* relative expression was the highest in patients with severe exacerbation, followed by the patients with moderate exacerbation and the lowest in patients with mild exacerbation. These data suggested that *lncRNA NEAT1* was positively correlated with exacerbation severity in patients with asthma in exacerbation.

![*LncRNA NEAT1* relative expression in patients with different exacerbation severity. Correlation of *lncRNA NEAT1* relative expression with the asthma exacerbation severity (mild, moderate, severe) was analyzed by Spearman\'s rank correlation test. *P* \< .05 was considered significant. *LncRNA NEAT1*, *long non‐coding RNA nuclear‐enriched abundant transcript 1*](JCLA-34-e23023-g002){#jcla23023-fig-0002}

3.4. Correlation of *lncRNA NEAT1* with clinical characteristics {#jcla23023-sec-0018}
----------------------------------------------------------------

In patients with asthma in exacerbation, *lncRNA NEAT1* relative expression was positively correlated with TNF‐α (*r* = .429, *P* \< .001), IL‐1β (*r* = .342, *P* \< .001), and IL‐17 (*r* = .416, *P* \< .001), but negatively correlated with FEV~1~/FVC (*r* = −.356, *P* \< .001), FEV~1~%predicted (*r* = −.273, *P* \< .001), and IL‐10 (*r* = −.298, *P* \< .001) (Table [2](#jcla23023-tbl-0002){ref-type="table"}). In patients with asthma in remission, *lncRNA NEAT1* relative expression was positively correlated with TNF‐α (*r* = .253, *P* = .001), IL‐1β (*r* = .221, *P* = .004), and IL‐17 (*r* = .330, *P* \< .001), but negatively correlated with FEV~1~/FVC (*r* = −.170, *P* = .026) and IL‐10 (*r* = −.207, *P* = .007). In HCs, *lncRNA NEAT1* was positively correlated with TNF‐α (*r* = .212, *P* = .006), IL‐1β (*r* = .167, *P* = .029), and IL‐17 (*r* = .213, *P* = .005), but negatively correlated with IL‐10 (*r* = −.269, *P* \< .001). These data suggested that *lncRNA NEAT1* positively correlated with poor lung function and higher inflammation, especially in patients with asthma in exacerbation.

###### 

Correlation of *lncRNA NEAT1* relative expression with clinical features

  Items              *LncRNA NEAT1* relative expression                                     
  ------------------ ------------------------------------ ------- -------- ------- -------- -------
  IgE                .182                                 .103    .465     .056    .384     −.067
  FEV~1~/FVC         \<.001                               −.356   .026     −.170   .768     .023
  FEV~1~%predicted   \<.001                               −.273   .723     .027    .616     .039
  TNF‐α              \<.001                               .429    .001     .253    .006     .212
  IL‐1β              \<.001                               .342    .004     .221    .029     .167
  IL‐10              \<.001                               −.298   .007     −.207   \<.001   −.269
  IL‐17              \<.001                               .416    \<.001   .330    .005     .213

Correlations were determined by Spearman\'s rank correlation test.

Abbreviations: FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; HCs, healthy controls; IgE, immune globulin E; IL, interleukin; LncRNA, long non‐coding RNA; r, correlation coefficient; TNF, tumor necrosis factor.
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3.5. Correlation of *lncRNA NEAT1* and *miR‐124* {#jcla23023-sec-0019}
------------------------------------------------

*LncRNA NEAT1* relative expression was negatively correlated with *miR‐124* relative expression in patients with asthma in exacerbation (*r* = −.384, *P* \< .001) (Figure [3](#jcla23023-fig-0003){ref-type="fig"}A), patients with asthma in remission (*r* = −.256, *P* = .001) (Figure [3](#jcla23023-fig-0003){ref-type="fig"}B), and HCs (*r* = −.295, *P* \< .001) (Figure [3](#jcla23023-fig-0003){ref-type="fig"}C). This indicated that *lncRNA NEAT1* was negatively correlated with *miR‐124* especially in patients with asthma in exacerbation. *MiR‐124* relative expression was lower in patients with asthma in exacerbation compared with patients with asthma in remission (*P* \< .001) and HCs (*P* \< .001); however, it was similar between patients with asthma in remission and HCs (*P* = .187) (Figure [3](#jcla23023-fig-0003){ref-type="fig"}D). ROC curve exhibited that *miR‐124* was of good value in distinguishing patients with asthma in exacerbation from HCs (AUC: 0.813 (0.769‐0.857)) (Figure [3](#jcla23023-fig-0003){ref-type="fig"}E) and patients with asthma in remission (AUC: 0.759 (0.746‐0.843)) (Figure [3](#jcla23023-fig-0003){ref-type="fig"}F), but it could not differentiate patients with asthma in remission from HCs (AUC: 0.578 (0.516‐0.641) (Figure [3](#jcla23023-fig-0003){ref-type="fig"}G). These data suggested that *lncRNA NEAT1* might contribute to the asthma exacerbation through the interaction with *miR‐124*.

![Correlation of *lncRNA NEAT1* and *miR‐124* in asthma. The correlations of *lncRNA NEAT1* and *miR‐124* in patients with asthma in exacerbation (A), patients with asthma in remission (B), and HCs (C). The comparisons of *miR‐124* relative expression among HCs, patients with asthma in remission, and patients with asthma in exacerbation (D). The performances of *miR‐124* in distinguishing patients with asthma in exacerbation from HCs (E), patients with asthma in exacerbation from patients with asthma in remission (F), and patients with asthma in remission from HCs (G). The correlations of *lncRNA NEAT1* and *miR‐124* were conducted by Spearman\'s rank correlation test. Comparisons among three groups were conducted by Kruskal‐Wallis test followed by the Dunn\'s multiple comparisons test. And ROC curves were used to assess the ability of *miR‐124* in distinguishing HCs, patients with asthma in remission, and patients with asthma in exacerbation. *P* \< .05 was considered significant. *LncRNA NEAT1*, *long non‐coding RNA nuclear‐enriched abundant transcript 1*; *miR‐124*, *microRNA‐124*; HCs, healthy controls; ROC, receiver operating characteristic](JCLA-34-e23023-g003){#jcla23023-fig-0003}

3.6. Correlation of *miR‐124* with clinical characteristics {#jcla23023-sec-0020}
-----------------------------------------------------------

In patients with asthma in exacerbation, *miR‐124* relative expression was positively correlated with FEV~1~/FVC (*r* = .503, *P* \< .001), FEV~1~% predicted (*r* = .509, *P* \< .001), and IL‐10 (*r* = .260, *P* = .001) but negatively correlated with TNF‐α (*r* = −.387, *P* \< .001), IL‐1β (*r* = −.348,*P* \< .001), IL‐17 (*r* = −.244, *P* = .001), and exacerbation severity (*r* = −.665,*P* \< .001) (Table [3](#jcla23023-tbl-0003){ref-type="table"}). In patients with asthma in remission, *miR‐124* relative expression was positively correlated with IL‐10 (*r* = .204, *P* = .008), but negatively correlated with IgE (*r* = −.213, *P* = .005), TNF‐α (*r* = −.171, *P* = .026), and IL‐17 (*r* = −.330, *P* \< .001). And in HCs, *miR‐124* relative expression was positively correlated with FEV~1~/FVC (*r* = .221, *P* = .004) and IL‐10 (*r* = .222, *P* = .004), but negatively correlated with TNF‐α (*r* = −.220, *P* = .004), IL‐1β (*r* = −.190, *P* = .013), and IL‐17 (*r* = −.297, *P* \< .001). Data above suggested that *miR‐124* was positively correlated with lung function, but negatively associated with inflammation, especially in patients with asthma in exacerbation. And *miR‐124* was negatively associated with exacerbation severity in patients with asthma in exacerbation.

###### 

Correlation of *miR‐124* relative expression with clinical features

  Items                   *MiR‐124* relative expression                                     
  ----------------------- ------------------------------- ------- -------- ------- -------- -------
  IgE                     .189                            −.101   .005     −.213   .326     .076
  FEV~1~/FVC              \<.001                          .503    .579     −.043   .004     .221
  FEV~1~%predicted        \<.001                          .509    .416     −.063   .460     −.057
  TNF‐α                   \<.001                          −.387   .026     −.171   .004     −.220
  IL‐1β                   \<.001                          −.348   .126     −.118   .013     −.190
  IL‐10                   .001                            .260    .008     .204    .004     .222
  IL‐17                   .001                            −.244   \<.001   −.330   \<.001   −.297
  Exacerbation severity   \<.001                          −.665   --       --      --       --

Correlations were determined by Spearman\'s rank correlation test.

Abbreviations: FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; HCs, healthy controls; IgE, immune globulin E; IL, interleukin; r, correlation coefficient; TNF, tumor necrosis factor.
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3.7. Correlation of medications with *lncRNA‐NEAT1*, *miR‐124*, and *lncRNA NEAT1/miR‐124* axis {#jcla23023-sec-0021}
-----------------------------------------------------------------------------------------------

In patients with asthma in remission, there was no difference of *miR‐124* (*P* = .216), *lncRNA NEAT1* (*P* = .741), and *lncRNA NEAT1/miR‐124* axis (*P* = .756) expressions among patients without use of medicine and the patients who had medication of ICS and ICS + LTRA (Table [S2](#jcla23023-sup-0002){ref-type="supplementary-material"}). As for in patients with asthma in exacerbation, there was also no difference of *miR‐124* (*P* = .964), *lncRNA NEAT1* (*P* = .580), and *lncRNA NEAT1/miR‐124* axis (*P* = .986) expressions among patients with medication of ICS + β2‐agonists, ICS + β2‐agonists + theophylline, ICS + β2‐agonists + anticholinergics, and ICS + β2‐agonists + anticholinergics+anti‐IgE antibody. Data above indicated that medications did not affect *lncRNA‐NEAT1*, *miR‐124, and lncRNA NEAT1/miR‐124* axis.

4. DISCUSSION {#jcla23023-sec-0022}
=============

In the present study, *lncRNA NEAT1* was of good value in differentiating patients with asthma in exacerbation from patients with asthma in remission as well as HCs, especially in predicting asthma exacerbation risk, and it was positively associated with exacerbation severity in asthma patients with exacerbation. Furthermore, it was positively correlated with pro‐inflammatory cytokines, while negatively correlated with anti‐inflammatory cytokine and lung function in asthma patients. Meanwhile, *lncRNA NEAT1* was negatively correlated with *miR‐124*, and *miR‐124* was associated with decreased risk of asthma exacerbation, reduced exacerbation severity, improved lung function, and less inflammation.

Recent evidence indicates that *lncRNA NEAT1* plays an important role in the transcriptional regulation of cytokines (such as: interleukin‐8 (IL‐8)) in a viral infection, and it stimulates the activation of several inflammasomes (such as NLRP3, NLRC4, and AIM2 inflammasomes), which leads to immune response in immunoinflammatory diseases.[10](#jcla23023-bib-0010){ref-type="ref"}, [17](#jcla23023-bib-0017){ref-type="ref"} And the involvement of *lncRNA NEAT1* in immune system has been explored in several diseases including sepsis, systemic lupus erythematosus (SLE), mild dengue, and herpes simples.[17](#jcla23023-bib-0017){ref-type="ref"}, [18](#jcla23023-bib-0018){ref-type="ref"}, [19](#jcla23023-bib-0019){ref-type="ref"} For example, *lncRNA NEAT1* expression in peripheral blood mononuclear cells is remarkably increased in sepsis patients than that in HCs, and ROC curve illustrates that *lncRNA NEAT1* is of good value in predicting sepsis risk with AUC 0.851 (0.812‐0.935).[20](#jcla23023-bib-0020){ref-type="ref"} In addition, upregulation of *lncRNA NEAT1* promotes ROS production and endoplasmic reticulum (ER) stress‐regulated cardiomyocyte apoptosis, aggravating the severity of ischemia‐reperfusion injury.[21](#jcla23023-bib-0021){ref-type="ref"}, [22](#jcla23023-bib-0022){ref-type="ref"} Mechanically, increased serum level of ROS is a risk factor for high degree of airway obstruction, worse immune response, and asthma exacerbation, and ER stress induces the abnormal apoptosis as well as dysfunction of airway epithelial, which suggests the promoting role of *lncRNA NEAT1* for the higher risk of exacerbation in asthma.[22](#jcla23023-bib-0022){ref-type="ref"} Therefore, we deduced that *lncRNA NEAT1* might be involved in the asthma exacerbation. However, no study to date has been conducted. In our study, *lncRNA NEAT1* expression was notably higher in patients with asthma in exacerbation compared with patients with asthma in remission and HCs. ROC curves revealed a good predictive value of *lncRNA NEAT1* for asthma exacerbation risk, and it was positively correlated with exacerbation severity. The possible reasons might be that (a) *LncRNA NEAT1* might enhance the airway epithelial fibrosis and injury via promoting oxidative stress and ER stress, resulting in airway hyperplasia and airway narrowing in a longer period, thereby increasing the risk of asthma exacerbation.[21](#jcla23023-bib-0021){ref-type="ref"}, [23](#jcla23023-bib-0023){ref-type="ref"} (b) Considering *lncRNA NEAT1* was of pro‐inflammatory biological property, it might elevate the expression of pro‐inflammatory cytokines and stimulate inflammatory responses, thus increasing susceptibility to asthma exacerbation, which was validated by analyzing association of *lncRNA NEAT1* with inflammatory cytokines in our study.[10](#jcla23023-bib-0010){ref-type="ref"}

*LncRNA NEAT1* is reported to be a potential contributor to the elevated secretion of diverse cytokines in various diseases.[12](#jcla23023-bib-0012){ref-type="ref"}, [20](#jcla23023-bib-0020){ref-type="ref"}, [24](#jcla23023-bib-0024){ref-type="ref"} For example, *lncRNA NEAT1* is upregulated and its overexpression is correlated with the elevated expression of pro‐inflammatory chemokines and cytokines (IL‐1β, IL‐6, CXCL10, etc), increased clinical disease activity, and higher disease severity in patients with SLE.[12](#jcla23023-bib-0012){ref-type="ref"} However, the association of *lncRNA NEAT1* with inflammatory cytokines has not been explored in asthma yet; thus, we conducted related analysis in patients with asthma and observed that *lncRNA NEAT1* was positively associated with pro‐inflammatory cytokines while negatively correlated with anti‐inflammatory cytokine and lung function in patients with asthma. The possible reasons might include that (a) expression of *lncRNA NEAT1* was activated during the asthma exacerbation, enhancing continuous release of inflammatory factors and cytokines via activating multiple signaling pathways (such as the JNK/ERK MAPK signaling pathways) and inhibiting the anti‐inflammatory miRNAs, accelerating the inflammatory, and leading to the elevated exacerbation severity in patients with asthma. (b) During the acute exacerbation, when the immunity response was abnormally active, and inflammation response was extremely strong, the dysregulation of *lncRNA NEAT1* might be aggravated; thus, the association of *lncRNA NEAT1* with inflammation and lung function was more obvious during the exacerbation.

The ceRNA hypothesis proposes that numerous lncRNA might serve as molecular sponges for miRNAs to further influence target mRNA expression, which suggests the importance of such interactions in the progression of disease.[25](#jcla23023-bib-0025){ref-type="ref"} And it is reported that *lncRNA NEAT1* facilitates tumorigenesis and development of ovarian cancer cells as well as nasopharyngeal carcinoma via inhibiting *miR‐124*‐mediated signaling pathway.[14](#jcla23023-bib-0014){ref-type="ref"} Besides, *miR‐124* overexpression results in the downregulation of pro‐inflammatory markers and upregulation of anti‐inflammatory markers in lung residence macrophages, suggesting the anti‐inflammatory role of *miR‐124* in asthma exacerbation.[15](#jcla23023-bib-0015){ref-type="ref"} In order to further understand the possible mechanism of *lncRNA NEAT1* in asthma exacerbation, we explored the association of *lncRNA NEAT1* with *miR‐124* in asthma patients and found that *lncRNA NEAT1* expression was negatively associated with *miR‐124*. Additionally, *miR‐124* was negatively correlated with high risk of asthma exacerbation, exacerbation severity, and inflammation, but positively associated with lung function. These data suggested that *lncRNA NEAT1* might implicate in the asthma exacerbation through the interaction with *miR‐124*.

There were some limitations in this study: (a) Patients with cardiac asthma were excluded in our study; therefore, the results might not be suitable for all patients with asthma. (b) The detailed mechanism of *lncRNA NEAT1* and *miR‐124* in asthma exacerbation was not investigated; thus, further cellular experiments were needed to be conducted in the future. (b) This study was a single‐center, case‐control study, and the patients were from one region; thus, selection bias might exist.

In conclusion, circulating *lncRNA NEAT1* exhibits potential to be a new biomarker for elevated exacerbation risk and severity of asthma.
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